文献速递肾移植

美国肾移植受者三十年间癌症发病率与结局变化

Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period.
PubMed 文献 · Kidney Int · 2020-11-05

该研究利用美国移植与癌症登记关联数据,分析1987-2016年三个十年间101,014例成人肾移植受者。结果显示癌症总体及六种常见癌症发病率无显著变化,仅前列腺癌发病率显著下降。癌症诊断后四年内死亡伴功能移植(DWFG)风险达38%,移植物失败风险14%,肺癌后DWFG风险最高达78%。

要点

  • 三十年间肾移植受者癌症总体发病率无显著变化,仅前列腺癌下降。
  • 癌症诊断后四年内DWFG风险38%,移植物失败风险14%。
  • 肺癌后DWFG绝对风险最高达78%,其次结直肠癌49%、非霍奇金淋巴瘤38%、黑色素瘤35%。

核心结论

  • 美国肾移植受者三十年间癌症总体发病率无显著变化,癌症仍是重要致病和致死原因。

研究设计与样本

  • 利用美国移植与癌症登记关联数据,纳入101,014例成人肾移植受者,覆盖1987-1996、1997-2006、2007-2016三个十年。
  • 采用泊松回归评估癌症总体及七种常见癌症的发病率趋势,采用Cox回归评估癌症与死亡删失移植物失败(DCGF)及死亡伴功能移植(DWFG)风险的关联。

主要发现

  • 1987-2016年间癌症总体及六种常见癌症发病率无显著变化,仅前列腺癌在多变量调整后显著下降。
  • 非霍奇金淋巴瘤受者中DCGF和DWFG风险随时间显著下降,其他合并癌症无显著变化。
  • 2007-2016年移植受者癌症诊断后四年内,38%发生DWFG,14%发生移植物失败。
  • 肺癌后DWFG绝对风险78%,非霍奇金淋巴瘤38%,黑色素瘤35%,结直肠癌49%。

临床怎么用

  • 肾移植受者癌症负担持续存在,应重视移植后长期癌症监测与筛查。
  • 癌症诊断后移植物失败和死亡风险高,需加强癌症后移植物功能及生存管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recipients of kidney transplants have elevated cancer risk compared with the general population. Improvements over time in transplant care and cancer treatment may have affected incidence and outcomes of cancer among recipients of kidney transplant. To evaluate this, we used linked United States transplant and cancer registry data to study 101,014 adult recipients of kidney transplants over three decades (1987-1996, 1997-2006, 2007-2016). Poisson regression was used to assess trends in incidence for cancer overall and seven common cancers. Associations of cancer with risk of death-censored graft failure (DCGF) and death with functioning graft (DWFG) were evaluated with Cox regression. We also estimated absolute risks of DCGF and graft failure following cancer for recipients transplanted in 2007-2016. There was no significant change in the incidence of cancer overall or for six common cancers in recipients across the 1987-2016 period. Only the incidence of prostate cancer significantly decreased across this period after multivariate adjustment. Among recipients of kidney transplants with non-Hodgkin lymphoma, there were significant declines over time in elevated risks for DCGF and DWFG but no significant changes for other combined cancers. For recipients transplanted in the most recent period (2007-2016), risks following cancer diagnosis remained high, with 38% experiencing DWFG and 14% graft failure within four years of diagnosis. Absolute risk of DWFG was especially high following lung cancer (78%), non-Hodgkin lymphoma (38%), melanoma (35%), and colorectal cancer (49%). Thus, across a 30-year period in the United States, there was no overall change in cancer incidence among recipients of kidney transplants. Despite improvements for non-Hodgkin lymphoma, cancer remains a major cause of morbidity and mortality.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Blosser CD, Haber G, Engels EA, et al. Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period. Kidney Int. 2020. PMID: 33159960. doi:10.1016/j.kint.2020.10.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。